|
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia. |
|
|
Stock and Other Ownership Interests - Genmab |
|
|
|
Research Funding - Sarah Cannon Research Institute |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Karyopharm Therapeutics |
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Pharmacyclics; Sanofi |
|
|
Consulting or Advisory Role - TG Therapeutics |
Speakers' Bureau - AstraZeneca; Janssen; TG Therapeutics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Genentech; Gilead Sciences |
Speakers' Bureau - Bristol-Myers Squibb; Sanofi; Takeda; TG Therapeutics |
|
|
Employment - US Oncology Network |
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Beigene; Beigene; Bristol-Myers Squibb; Genentech; Merck; TG Therapeutics |
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst) |
|
|
|
Stock and Other Ownership Interests - Abbvie |
Other Relationship - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
No Relationships to Disclose |
|
|
Employment - Texas Oncology |
Consulting or Advisory Role - Abbvie; Jazz Pharmaceuticals; Seagen |
Speakers' Bureau - Abbvie; Amgen; Jazz Pharmaceuticals |
|
|
Consulting or Advisory Role - Abbvie; Seagen |
Research Funding - Incyte; Kite/Gilead; Novartis; Pfizer; PTC Therapeutics; Seagen |